381 related articles for article (PubMed ID: 17228487)
21. Cardiovascular effects of statins, beyond lipid-lowering properties.
Mihos CG; Pineda AM; Santana O
Pharmacol Res; 2014 Oct; 88():12-9. PubMed ID: 24631782
[TBL] [Abstract][Full Text] [Related]
22. Functional expression of human HMG-CoA reductase in Saccharomyces cerevisiae: a system to analyse normal and mutated versions of the enzyme in the context of statin treatment.
Wysocka-Kapcinska M; Lutyk-Nadolska J; Kiliszek M; Plochocka D; Maciag M; Leszczynska A; Rytka J; Burzynska B
J Appl Microbiol; 2009 Mar; 106(3):895-902. PubMed ID: 19187128
[TBL] [Abstract][Full Text] [Related]
23. Recent developments in the effects of nitric oxide-donating statins on cardiovascular disease through regulation of tetrahydrobiopterin and nitric oxide.
Ma S; Ma CC
Vascul Pharmacol; 2014 Nov; 63(2):63-70. PubMed ID: 25139660
[TBL] [Abstract][Full Text] [Related]
24. Recent development in the effects of statins on cardiovascular disease through Rac1 and NADPH oxidase.
Kwok JM; Ma CC; Ma S
Vascul Pharmacol; 2013 Jan; 58(1-2):21-30. PubMed ID: 23085091
[TBL] [Abstract][Full Text] [Related]
25. Pleiotropic vascular protective effects of statins in perioperative medicine.
Fang SY; Roan JN; Luo CY; Tsai YC; Lam CF
Acta Anaesthesiol Taiwan; 2013 Sep; 51(3):120-6. PubMed ID: 24148741
[TBL] [Abstract][Full Text] [Related]
26. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
[TBL] [Abstract][Full Text] [Related]
27. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia.
Miida T; Hirayama S; Nakamura Y
J Atheroscler Thromb; 2004; 11(5):253-64. PubMed ID: 15557707
[TBL] [Abstract][Full Text] [Related]
28. One statin, two statins, three statins, more: similarities and differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Turkoski BB
Orthop Nurs; 2011; 30(1):62-5; quiz 66-7. PubMed ID: 21278557
[TBL] [Abstract][Full Text] [Related]
29. Pleiotropic effects of statins and related pharmacological experimental approaches.
Alegret M; Silvestre JS
Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
[TBL] [Abstract][Full Text] [Related]
30. Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.
Sawada N; Liao JK
Antioxid Redox Signal; 2014 Mar; 20(8):1251-67. PubMed ID: 23919640
[TBL] [Abstract][Full Text] [Related]
31. The role of pleiotropic effects of statins in dementia.
Crisby M
Acta Neurol Scand Suppl; 2006; 185():115-8. PubMed ID: 16866920
[TBL] [Abstract][Full Text] [Related]
32. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation.
Arnaud C; Mach F
Arch Mal Coeur Vaiss; 2005 Jun; 98(6):661-6. PubMed ID: 16007821
[TBL] [Abstract][Full Text] [Related]
33. Pleiotropic effects of statins: moving beyond cholesterol control.
Garcia PJ
Curr Atheroscler Rep; 2005 Feb; 7(1):34-9. PubMed ID: 15683600
[TBL] [Abstract][Full Text] [Related]
34. The evolving role of statins in the management of atherosclerosis.
Vaughan CJ; Gotto AM; Basson CT
J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252
[TBL] [Abstract][Full Text] [Related]
35. Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?
Balakumar P; Mahadevan N
Br J Pharmacol; 2012 Jan; 165(2):373-9. PubMed ID: 21790534
[TBL] [Abstract][Full Text] [Related]
36. Pleiotropic effects and cholesterol-lowering therapy.
Shaw SM; Fildes JE; Yonan N; Williams SG
Cardiology; 2009; 112(1):4-12. PubMed ID: 18577880
[TBL] [Abstract][Full Text] [Related]
37. Pleiotropic properties of statins via angiogenesis modulation in cardiovascular disease.
Zahedipour F; Butler AE; Eid AH; Sahebkar A
Drug Discov Today; 2022 Oct; 27(10):103325. PubMed ID: 35872297
[TBL] [Abstract][Full Text] [Related]
38. [The non-lipid effects of statins].
Paragh G; Márk L; Katona E
Orv Hetil; 2004 Sep; 145(37):1903-10. PubMed ID: 15493621
[TBL] [Abstract][Full Text] [Related]
39. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
Mason RP; Walter MF; Day CA; Jacob RF
Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
[TBL] [Abstract][Full Text] [Related]
40. Lipid-lowering therapy. New and established agents reduce risk of cardiovascular events.
Smith CR
Postgrad Med; 2004 Mar; 115(3):29-30, 33-6. PubMed ID: 15038253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
